Dyadic International, Inc

Dyadic International is a U.S.-based biotechnology platform company that develops microbial protein production systems for industrial, life sciences, food and nutrition, and bio-industrial applications. It has no approved products for sale today and instead monetizes its C1 and Dapibus platforms through research collaborations, government grants, sublicensing, and related development services.

24,9 %

−238,3 %

−11,6 %

2.68

2.68

— Dyadic International, Inc
%
Protein production platforms45% Core microbial expression systems used to produce commercial quantities of proteins and enzymes.
Research collaboration services35% R&D services performed under collaboration agreements and government or commercial projects.
Sublicensing and technology transfer15% License-related arrangements, upfront fees, milestones, and potential royalties from platform IP.
Applied biotech programs5% Targeted development programs in food, nutrition, life sciences, and bio-industrial markets.

Dyadic sells primarily to collaboration partners, licensees, and research sponsors rather than end consumers...

  • Collaboration partnersprimary

    Partners fund research and development work and may pursue future licenses or commercialization rights.

  • Licensees and sublicense counterpartiesprimary

    Companies that pay for access to Dyadic's platform IP, technology transfer, or milestone-based rights.

  • Government and grant-funded sponsorssecondary

    Public or quasi-public programs that fund research projects and platform development.

  • European customerssecondary

    Non-U.S. customers that buy research services or collaboration access and diversify the revenue base geographically.

  • Contract research organizationssecondary

    CROs are not customers in the usual sense but are critical service providers enabling Dyadic's research execution.

Dyadic is headquartered in Jupiter, Florida and operates in the United States with a satellite office and foreign...

  • •Headquartered in Jupiter, Florida, United States
  • •Operates a foreign subsidiary and satellite office in the Netherlands
  • •Revenue comes from U.S. and European customers
  • •European customers represented 26.8% of 9M 2025 revenue
  • •Cross-border operations increase FX, tax, and compliance complexity

Dyadic is shifting from a research-driven organization toward a more commercially focused biotechnology platform under...

01
Commercialize the C1 and Dapibus platformsmedium-term

The company has no approved products, so platform monetization is the main path to durable revenue.

02
Build applied biotech partnershipsshort-term

Partnerships can fund development, validate the platform, and create downstream licensing opportunities.

03
Maintain liquidity and access to capitalshort-term

The company expects continued operating losses and may need external financing to fund development.

Dyadic remains a pre-commercial biotechnology company, so its results depend on successful platform validation, partner...

high

Customer concentration

A small number of customers accounted for most revenue and receivables, so losing one could materially reduce sales and cash flow.

Scope
Three customers accounted for 67.4% of 9M 2025 revenue
Materiality
high
high

Dependence on CROs

Research execution is outsourced to a few contract research organizations, creating operational dependency and potential delays or cost overruns.

Scope
Two CROs accounted for 87.6% of research services purchased in 9M 2025
Materiality
high
high

Capital needs and dilution

The company expects continued operating losses and may need to raise external capital to fund R&D and commercialization.

Scope
Potential equity, debt, or collaboration financing
Materiality
high
high

Commercialization and regulatory risk

The platforms must gain market acceptance and, for some programs, regulatory clearance before meaningful product revenue can emerge.

Scope
Microbial protein platforms and vaccine-related programs
Materiality
high
medium

Intellectual property risk

Value depends on protecting proprietary platform technology and license rights from challenge or obsolescence.

Scope
C1 and Dapibus platforms
Materiality
medium
Revenue recognition under ASC 606
Can shift revenue between quarters and affect comparability
Contract assets and deferred revenue
Affects working capital and reported revenue timing
Research and development expense recognition
Drives operating loss volatility
Stock-based compensation
Can materially affect reported operating costs
Investment securities and cash equivalents
Affects liquidity disclosure and interest income

DYADIC INTERNATIONAL INC

DYAI · Biological Products, (No Diagnostic Substances)

Dometic Group

DOM.ST · Consumer Discretionary

DMC Global Inc.

BOOM · Miscellaneous Primary Metal Products

MANNKIND CORP

MNKD · Pharmaceutical Preparations

AFLAC INC

AFL · Accident & Health Insurance

D. Boral ARC Acquisition I Corp.

BCAR · Services-Prepackaged Software

: 28/04/2026